Difficulty: Medium
Average Score: 94%
Practice
A 58-year-old woman who is obese comes to the emergency department with diaphoresis and crushing chest pain that radiates to her left arm. The physician orders an ECG and checks her cardiac enzymes to confirm his suspicion of myocardial infarction. Because of the quick response and intervention, she survives and is ultimately discharged with a prescription for low-dose daily aspirin to inhibit platelet aggregation. Which of the following enzymes is the intended target of aspirin in this patient?
Correct answer
A
Rationale
In this scenario, the correct answer is A) Cyclooxygenase. Aspirin inhibits cyclooxygenase, specifically the COX-1 and COX-2 enzymes, which are responsible for the conversion of arachidonic acid into prostaglandins and thromboxanes. By inhibiting cyclooxygenase, aspirin reduces the production of thromboxane A2, a potent platelet aggregator, thus preventing platelet aggregation and reducing the risk of thrombosis in conditions like myocardial infarction.
Regarding the other options:
B) Lipoxygenase: Lipoxygenase is not the target enzyme of aspirin in this context. Lipoxygenase is involved in the synthesis of leukotrienes, not thromboxanes.
C) Phospholipase A2: Phospholipase A2 is not the target enzyme of aspirin in this scenario. Phospholipase A2 is involved in the release of arachidonic acid from cell membranes, which is a precursor for prostaglandin synthesis.
D) Prostacyclin synthase: Aspirin does not target prostacyclin synthase. Prostacyclin synthase is responsible for the synthesis of prostacyclin, which has anti-aggregatory effects, contrary to thromboxane A2.
Educationally, understanding the mechanism of action of medications like aspirin is crucial for healthcare professionals to make informed decisions in patient care. Knowing how aspirin works in inhibiting platelet aggregation helps in managing conditions like myocardial infarction effectively and preventing complications. This knowledge also underscores the importance of individualized treatment plans based on a patient's condition and medication mechanism of action.
Regarding the other options:
B) Lipoxygenase: Lipoxygenase is not the target enzyme of aspirin in this context. Lipoxygenase is involved in the synthesis of leukotrienes, not thromboxanes.
C) Phospholipase A2: Phospholipase A2 is not the target enzyme of aspirin in this scenario. Phospholipase A2 is involved in the release of arachidonic acid from cell membranes, which is a precursor for prostaglandin synthesis.
D) Prostacyclin synthase: Aspirin does not target prostacyclin synthase. Prostacyclin synthase is responsible for the synthesis of prostacyclin, which has anti-aggregatory effects, contrary to thromboxane A2.
Educationally, understanding the mechanism of action of medications like aspirin is crucial for healthcare professionals to make informed decisions in patient care. Knowing how aspirin works in inhibiting platelet aggregation helps in managing conditions like myocardial infarction effectively and preventing complications. This knowledge also underscores the importance of individualized treatment plans based on a patient's condition and medication mechanism of action.